Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Buy" from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been given a consensus recommendation of "Buy" by the nine brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $22.5556.

Several equities analysts have recently commented on CAPR shares. B. Riley started coverage on Capricor Therapeutics in a research report on Thursday, June 26th. They issued a "buy" rating and a $21.00 price objective on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 target price on shares of Capricor Therapeutics in a research note on Friday, July 11th. Oppenheimer lowered their target price on Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a report on Monday, June 23rd. Alliance Global Partners reiterated a "buy" rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Nuveen Asset Management LLC boosted its position in Capricor Therapeutics by 392.7% during the fourth quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock worth $2,334,000 after acquiring an additional 134,791 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in Capricor Therapeutics during the 4th quarter worth $183,000. The Manufacturers Life Insurance Company increased its stake in Capricor Therapeutics by 22.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after buying an additional 2,361 shares during the period. Two Sigma Investments LP grew its holdings in Capricor Therapeutics by 223.6% during the 4th quarter. Two Sigma Investments LP now owns 119,047 shares of the biotechnology company's stock worth $1,643,000 after acquiring an additional 82,254 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after acquiring an additional 241,279 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Stock Up 4.3%

NASDAQ:CAPR opened at $8.07 on Friday. The stock has a market cap of $368.64 million, a P/E ratio of -5.68 and a beta of 0.59. The business's 50-day moving average price is $9.61 and its two-hundred day moving average price is $11.25. Capricor Therapeutics has a twelve month low of $3.71 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter last year, the business posted ($0.31) EPS. On average, equities research analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.